ORCA Therapeutics welcomes Industry Veteran Joern Skibsted Jakobsen to its Scientific Advisory Board

Amsterdam, The Netherlands – January 2026

ORCA Therapeutics, a clinical-stage biopharmaceutical company advancing oncolytic immunotherapies for cancer treatment, is pleased to announce the appointment of Dr. Joern Skibsted Jakobsen to its Scientific Advisory Board (SAB).

Dr. Jakobsen brings extensive pharmaceutical industry expertise from his current role as Vice President and Therapeutic Area Head for Uro-oncology & Urology at Ferring Pharmaceuticals. In this leadership capacity, he has been instrumental in the development and commercialization of innovative gene therapies in urology and oncology. Notably, he played a key role in advancing adstiladrin (nadofaragene firadenovec), a groundbreaking adenoviral gene therapy for high-risk non-muscle invasive bladder cancer that represents one of the first approved gene therapies in urology-oncology. His deep understanding of gene therapy development, regulatory strategy, and cross-functional team leadership in the urology-oncology landscape makes him an exceptional addition to ORCA’s advisory team.

“We are delighted to welcome Joern to ORCA’s Scientific Advisory Board,” said CEO Wenliang Dong. “His hands-on experience developing and commercializing adenoviral gene therapies in urology-oncology is directly relevant to our mission. As a therapeutic area head at Ferring, Joern has demonstrated the strategic insights and understanding of the regulatory and commercial pathways for novel therapeutics that will be invaluable as we advance ORCA-010 through clinical development in prostate cancer and pursue strategic partnerships.”

“I am very pleased to join the Scientific Advisory Board of ORCA Therapeutics at this pivotal stage. “ said Dr. Jakobsen. “With more than 20 years of clinical experience in prostate cancer, including extensive surgical practice and service on the board of the Scandinavian Prostate Cancer Group (SPCG), combined with eight years in global oncology drug development, I bring a translational perspective that bridges biology, clinical strategy, and regulatory execution. I look forward to supporting ORCA in advancing its oncolytic virus immunotherapy platform toward clinically differentiated solutions that not only create strategic value but, most importantly, improve outcomes and quality of life for patients facing this disease.”

Throughout his tenure at Ferring, including his previous role as Global Medical Director for R&D in Urology/Uro-oncology, Mr. Jakobsen has developed particular expertise in viral vector-based therapies and the unique challenges of developing localized immunotherapies for urological malignancies. His understanding of both clinical development and market access strategy will support ORCA as the company advances its groundbreaking platform that has demonstrated 100% immune activation in prostate cancer patients, converting immunologically “cold” tumors into “hot” tumors.

Dr. Jakobsen’s appointment to ORCA’s SAB strengthens the company’s advisory network and underscores its commitment to building world-class expertise across scientific, clinical, and commercial domains. His guidance will be particularly valuable as ORCA executes its fundraising strategy and advances the development of ORCA-010 for cancer.

About ORCA-010

ORCA-010 is a first-in-class oncolytic immunotherapy designed to kill cancer cells directly while deregulating the tumor microenvironment and transforming immunologically “cold” tumors into “hot” tumors, enabling the patient’s immune system to recognize and attack cancer cells. In Phase I/IIA clinical trials in prostate cancer, ORCA-010 demonstrated 100% immune activation across all treated patients and inducing a systemic anti-tumor immune response. The therapy’s unique mechanism of action combines direct oncolytic activity with robust immune system engagement, offering potential application across multiple solid tumor types. ORCA Therapeutics is currently advancing ORCA-010’s development in prostate cancer while exploring expansion into additional orphan indications through strategic academic collaborations.

About ORCA Therapeutics BV

Media Contact

Dr. Wenliang Dong, Ph.D., MBA
CEO, ORCA Therapeutics BV
Email: info@orca-therapeutics.com
Website: www.orca-therapeutics.com